Follow us

Contributed By:

Jessica Kittams

OHSU Researcher Criticizes Drug Prices

OPB | April 29, 2013 12:35 p.m. | Updated: Sept. 11, 2013 12:45 a.m.

Brian Druker, director of the Knight Cancer Institute at OHSU, is critical of pharmaceutical companies’ profit margins. He co-authored a newly published letter in a the medical journal Blood criticizing the expense of a drug he helped develop. That drug, Gleevec, is now used by over 200,000 cancer patients worldwide, and can cost up to $100,000 a year. Dr. Druker hopes to begin working with lawmakers to change the way pharmaceutical companies price their drugs.

Have you or a loved one been through cancer treatment? What were the financial barriers to your treatment? Would you support governmental regulating pharmaceutical pricing?

Comments

blog comments powered by Disqus
Thanks to our Sponsors:
become a sponsor

Related

Thanks to our Sponsors
become a sponsor

Funding Provided By

Rose E. Tucker Charitable Trust

James F. and Marion L. Miller Foundation

Dawn and Al Vermeulen

Ray and Marilyn Johnson